In COVID-19, ACE2 showed opposite harmful effects as an entry point, and beneficial effect by counteracting the overstimulated RAS as it degrades AngII to angiotensin 1–7 (Ang1–7) (Kuster et al., 2020). The gene discussed is ACE2; the disease is COVID-19.